Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change
02/26/02	€0.4750	0.00%
01/26/01	€0.4750	-4.81%
30/26/30	€0.4990	-13.07%
29/26/29	€0.5740	0.00%
28/26/28	€0.5740	-6.51%

Delayed Quote Deutsche Boerse AG

More quotes

Delayed Deutsche Boerse AG 11:30:53 02/10/2026 am IST			5-day change	1st Jan Change
0.4750 ^EUR	0.00%		-22.64%	-39.41%

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	28.76L 32.38L 26.9L 24.51L 46.15L 31Cr 46.78L 3.25Cr 1.26Cr 16Cr 1.22Cr 1.19Cr 51Cr	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	39.57L 44.55L 37L 33.72L 63.48L 43Cr 64.36L 4.48Cr 1.73Cr 22Cr 1.67Cr 1.64Cr 70Cr	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Deutsche Boerse AG	4YA	Delayed
Börse Stuttgart	4YA	Delayed
Boerse Muenchen	4YA	Real-time

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/24/16	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/24/15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/23/07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/23/27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/23/28	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/23/09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/22/23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/22/14	Twitter to shut down newsletter product Revue next year	RE
06/22/06	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/22/06	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

Klarsen Share Price Deutsche Boerse AG

Stocks

4YA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news: Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Price Extremes

Managers and Directors: Klarsen

Other IT Services & Consulting

Financials

Company Profile

Quotes

03/03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
25/02	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
10/12	Klarsen : ALKLA-Attribution gratuite de BSA	PU
09/12	Klarsen : ALKLA-ACTIVITE 3T2025	PU
27/11	Klarsen : ALKLA-Résultat augmentation de capital	PU

08/09	Klarsen : calendrier de communication
08/09	Klarsen : ALKLA – Klarsen fait évoluer son calendrier de communication financière et rappelle la tenue de ses Assemblées Générales des 29 septembre et 8 octobre 2026 – 08 Septembre 2026
27/08	Klarsen : ALKLA – Présentation webinaire du 27/08/2026 – Support
27/08	Klarsen : Assemblée générale – 29 Septembre 2026
19/08	Bourse : série de résultats en Europe, flambée d'Unitree et puces Nvidia en Chine

1 week	-22.64%
Current month	-4.81%
1 month	-47.46%
3 months	-27.15%
6 months	-37.50%
Current year	-39.41%

1 week	0.48	0.61
1 month	0.48	0.84
Current year	0.2	1.38
1 year	0.2	1.38
3 years	0.2	3.62
5 years	0.2	3.83
10 years	0.2	4.14

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	0.00%	-22.64%	-	-	20.52L
IBM	+2.59%	-0.63%	-21.25%	+60.81%	21TCr
SALESFORCE, INC.	+3.10%	-0.64%	+0.42%	+16.72%	19TCr
CLOUDFLARE, INC.	+1.07%	-2.18%	+61.71%	+456.79%	12TCr
SNOWFLAKE INC.	+0.72%	+2.39%	+48.34%	+123.86%	12TCr
ACCENTURE PLC	+15.78%	+19.67%	-12.89%	-30.87%	13TCr
TATA CONSULTANCY SERVICES LTD.	+1.19%	-0.57%	-28.80%	-41.19%	7.8TCr
RELX PLC	+0.44%	-0.32%	-27.34%	-8.60%	5.77TCr
COREWEAVE, INC.	+1.66%	-1.73%	-35.37%	-	4.88TCr
FUJITSU LIMITED	+1.67%	+1.02%	+19.75%	+131.72%	4.41TCr
Average	+2.57%	+1.23%	+0.51%	+88.65%	11.2TCr
Weighted average by Cap.	+3.39%	+1.05%	+2.77%	+90.08%

	2023	2024
Net sales	50.26L 56.59L 47L 42.83L 80.64L 54Cr 81.74L 5.69Cr 2.2Cr 28Cr 2.12Cr 2.08Cr 89Cr	63.11L 71.05L 59.02L 53.78L 1.01Cr 68Cr 1.03Cr 7.14Cr 2.76Cr 35Cr 2.67Cr 2.61Cr 111.91Cr
Net income	27.51L 30.97L 25.72L 23.44L 44.13L 30Cr 44.74L 3.11Cr 1.2Cr 15Cr 1.16Cr 1.14Cr 49Cr	-47.76T -53.78T -44.67T -40.71T -76.63T -51.78L -77.69T -5L -2L -26.37L -2L -2L -84.7L
Net Debt	-6L -7L -6L -5L -10.18L -6.88Cr -10.32L -71.78L -27.79L -3.5Cr -26.82L -26.24L -11Cr	10.81L 12.17L 10.11L 9L 17.34L 12Cr 17.58L 1.22Cr 47.33L 5.97Cr 45.68L 44.69L 19Cr